VedaBio

About VedaBio

VedaBio is a biotechnology company founded in 2021 by Anurup Ganguli and Rashid Bashir that is developing a new paradigm in molecular detection. The company, formerly known as LabSimply, launched from stealth in October 2023 with over $40 million in initial funding led by OMX Ventures.

The firm's core technology is the CRISPR Cascade™ platform, which enables the ultra-rapid detection of multiple analytes with high accuracy, comparable to PCR standards. A key feature of this technology is that it eliminates the need for target amplification, a common step in traditional molecular diagnostics like PCR that can be time-consuming and complex. By forgoing amplification, the CRISPR Cascade platform can produce analytical results in under a minute. The technology employs engineered CRISPR enzymes to identify a target molecule and then amplify the detection signal through a positive feedback loop.

VedaBio was co-founded by CEO Anurup Ganguli, who developed related technologies at the University of Illinois at Urbana-Champaign, and Rashid Bashir, PhD, Dean of The Grainger College of Engineering at the same university. The company is led by President and CEO Frederic Sweeney, PhD, who brings extensive experience from roles at MeMed Diagnostics, bioMérieux, and T2 Biosystems. The company's business model focuses on applying this platform across various industries, including healthcare diagnostics, therapeutics, and research tools. It aims to provide rapid, accurate, and accessible diagnostic solutions for decentralized settings like urgent care clinics and outpatient facilities.

The company has secured significant partnerships and funding to advance its platform. In September 2025, VedaBio announced a strategic agreement with Siemens Healthineers and a Series A extension, totaling up to $25 million to propel its CRISPR-based product platform. It also has a non-exclusive licensing agreement with Mammoth Biosciences, which grants VedaBio access to foundational CRISPR intellectual property to accelerate the development of its diagnostic solutions.